|
1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Jelovac D and Armstrong DK: Recent
progress in the diagnosis and treatment of ovarian cancer. CA
Cancer J Clin. 61:183–203. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Thiery JP: Epithelial-mesenchymal
transitions in tumour progression. Nat Rev Cancer. 2:442–454. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Takai M, Terai Y, Kawaguchi H, Ashihara K,
Fujiwara S, Tanaka T, Tsunetoh S, Tanaka Y, Sasaki H, Kanemura M,
et al: The EMT (epithelial-mesenchymal-transition)-related protein
expression indicates the metastatic status and prognosis in
patients with ovarian cancer. J Ovarian Res. 7:762014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Liu Z, Yun R, Yu X, Hu H, Huang G, Tan B
and Chen T: Overexpression of Notch3 and pS6 is associated with
poor prognosis in human ovarian epithelial cancer. Mediators
Inflamm. 2016:59534982016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Loehrer PJ and Einhorn LH: Cisplatin. Ann
Intern Med. 100:704–713. 1984. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kartalou M and Essigmann JM: Mechanisms of
resistance to cisplatin. Mutat Res. 478:23–43. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Uchino H, Matsumura Y, Negishi T, Koizumi
F, Hayashi T, Honda T, Nishiyama N, Kataoka K, Naito S and Kakizoe
T: Cisplatin-incorporating polymeric micelles (NC-6004) can reduce
nephrotoxicity and neurotoxicity of cisplatin in rats. Br J Cancer.
93:678–687. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lu L, Schwartz P, Scarampi L, Rutherford
T, Canuto EM, Yu H and Katsaros D: MicroRNA let-7a: A potential
marker for selection of paclitaxel in ovarian cancer management.
Gynecol Oncol. 122:366–371. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Cancer Genome Atlas Research Network, .
Integrated genomic analyses of ovarian carcinoma. Nature.
474:609–615. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Patch AM, Christie EL, Etemadmoghadam D,
Garsed DW, George J, Fereday S, Nones K, Cowin P, Alsop K, Bailey
PJ, et al: Whole-genome characterization of chemoresistant ovarian
cancer. Nature. 521:489–494. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lalwani N, Prasad SR, Vikram R, Shanbhogue
AK, Huettner PC and Fasih N: Histologic, molecular, and cytogenetic
features of ovarian cancers: Implications for diagnosis and
treatment. Radiographics. 31:625–646. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hwang SY, Cho DY, Kim HK, Cho SH, Choo J,
Yoon WJ and Lee EK: Preparation of targeting proteoliposome by
postinsertion of a linker molecule conjugated with recombinant
human epidermal growth factor. Bioconjug Chem. 21:345–351. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Phillips TM, McBride WH and Pajonk F: The
response of CD24(−/low)/CD44+ breast cancer-initiating cells to
radiation. J Natl Cancer I. 98:1777–1785. 2006. View Article : Google Scholar
|
|
15
|
Kristiansen G, Denkert C, Schlüns K, Dahl
E, Pilarsky C and Hauptmann S: CD24 is expressed in ovarian cancer
and is a new independent prognostic marker of patient survival. Am
J Pathol. 161:1215–1221. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kristiansen G, Winzer KJ, Mayordomo E,
Bellach J, Schlüns K, Denkert C, Dahl E, Pilarsky C, Altevogt P and
Guski H: CD24 expression is a new prognostic marker in breast
cancer. Clin Cancer Res. 9:4906–4913. 2003.PubMed/NCBI
|
|
17
|
Zhu J, Zhang G and Lu H: CD24, COX-2, and
p53 in epithelial ovarian cancer and its clinical significance.
Front Biosci (Elite Ed). 4:2645–2651. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lee TK, Castilho A, Cheung VC, Tang KH, Ma
S and Ng IO: CD24(+) liver tumor-initiating cells drive
self-renewal and tumor initiation through STAT3-mediated NANOG
regulation. Cell Stem Cell. 9:50–63. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Nakamura K, Terai Y, Tanabe A, Ono YJ,
Hayashi M, Maeda K, Fujiwara S, Ashihara K, Nakamura M, Tanaka Y,
et al: CD24 expression is a marker for predicting clinical outcome
and regulates the epithelial-mesenchymal transition in ovarian
cancer via both the Akt and ERK pathways. Oncol Rep. 37:3189–3200.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yoshida M, Takimoto R, Murase K, Sato Y,
Hirakawa M, Tamura F, Sato T, Iyama S, Osuga T, Miyanishi K, et al:
Targeting anticancer drug delivery to pancreatic cancer cells using
a fucose-bound nanoparticle approach. PLoS One. 7:e395452012.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Hirai M, Minematsu H, Kondo N, Oie K,
Igarashi K and Yamazaki N: Accumulation of liposome with Sialyl
Lewis X to inflammation and tumor region: Application to in vivo
bio-imaging. Biochem Biophys Res Commun. 353:553–558. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Hirai M, Hiramatsu Y, Iwashita S, Otani T,
Chen L, Li YG, Okada M, Oie K, Igarashi K, Wakita H and Seno M:
E-selectin targeting to visualize tumors in vivo. Contrast Media
Mol Imaging. 5:70–77. 2010.PubMed/NCBI
|
|
23
|
Pollmann D, Broekaert JA, Leis F, Tschopel
P and Tolg G: Determination of boron in biological tissues by
inductively-coupled plasma optical-emission spectrometry (ICP-OES).
Fresen J Anal Chem. 346:441–445. 1993. View Article : Google Scholar
|
|
24
|
Duffy M and Thomas R: Benefits of a
dual-view ICP-OES for the determination of boron, phosphorus, and
sulfur in low alloy steels return to document menu. Atom Spectrosc.
17:128–132. 1996.
|
|
25
|
Lubura M, Hesse D, Neumann N, Scherneck S,
Wiedmer P and Schürmann A: Non-invasive quantification of white and
brown adipose tissues and liver fat content by computed tomography
in mice. PLoS One. 7:e370262012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Sano A, Kato H, Sakurai S, Sakai M, Tanaka
N, Inose T, Saito K, Sohda M, Nakajima M, Nakajima T and Kuwano H:
CD24 expression is a novel prognostic factor in esophageal squamous
cell carcinoma. Ann Surg Oncol. 16:506–514. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Blechschmidt K, Sassen S, Schmalfeldt B,
Schuster T, Höfler H and Becker KF: The E-cadherin repressor Snail
is associated with lower overall survival of ovarian cancer
patients. Br J Cancer. 98:489–495. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kawaguchi H, Terai Y, Tanabe A, Sasaki H,
Takai M, Fujiwara S, Ashihara K, Tanaka Y, Tanaka T, Tsunetoh S, et
al: Gemcitabine as a molecular targeting agent that blocks the Akt
cascade in platinum-resistant ovarian cancer. J Ovarian Res.
7:382014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Krantz SB, Shields MA, Dangi-Garimella S,
Munshi HG and Bentrem DJ: Contribution of epithelial-to-mesenchymal
transition and cancer stem cells to pancreatic cancer progression.
J Surg Res. 173:105–112. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Peer D, Karp JM, Hong S, Farokhzad OC,
Margalit R and Langer R: Nanocarriers as an emerging platform for
cancer therapy. Nat Nanotechnol. 2:751–760. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Levi FA, Hrushesky WJ, Halberg F, Langevin
TR, Haus E and Kennedy BJ: Lethal nephrotoxicity and hematologic
toxicity of cis-diammine-dichloroplatinum ameliorated by optimal
circadian timing and hydration. Eur J Cancer Clin Oncol.
18:471–477. 1982. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Peinado H, Olmeda D and Cano A: Snail, Zeb
and bHLH factors in tumour progression: An alliance against the
epithelial phenotype? Nat Rev Cancer. 7:415–428. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Taki M, Abiko K, Baba T, Hamanishi J,
Yamaguchi K, Murakami R, Yamanoi K, Horikawa N, Hosoe Y, Nakamura
E, et al: Snail promotes ovarian cancer progression by recruiting
myeloid-derived suppressor cells via CXCR2 ligand upregulation. Nat
Commun. 9:16852018. View Article : Google Scholar : PubMed/NCBI
|
